GCP
XLO icon

GSA Capital Partners’s Xilio Therapeutics XLO Stock Holding History

GSA Capital Partners’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
13,590
-3,356
-20% -$28K 0.01% 1601
2026
Q1 		$143K Buy
16,946
+6,377
+60% +$52.2K 0.01% 1517
2025
Q4 		$95K Buy
+10,569
New +$111K 0.01% 1535

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSA Capital Partners's XLO Position: Q2 2026 in Review

GSA Capital Partners reduced its Xilio Therapeutics (XLO) stake by 20% in Q2 2026, selling an estimated $28K and leaving 13,590 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #1601.

GSA Capital Partners first reported a position in XLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $143K in Q1 2026. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • GSA Capital Partners held 13,590 shares of Xilio Therapeutics worth $130K as of Q2 2026.
  • GSA Capital Partners sold 3,356 Xilio Therapeutics shares in Q2 2026, an estimated $28K.
  • Xilio Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1601 holding.
  • GSA Capital Partners first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GSA Capital Partners's Xilio Therapeutics position peaked at $143K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.